- Home
- XNCR vs DVAX Comparison
XNCR vs DVAX Comparison
Compare XNCR & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNCR
- DVAX
- Stock Information
- Founded
- XNCR 1997
- DVAX 1996
- Country
- XNCR United States
- DVAX United States
- Employees
- XNCR N/A
- DVAX N/A
- Industry
- XNCR Biotechnology: Pharmaceutical Preparations
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- XNCR Health Care
- DVAX Health Care
- Exchange
- XNCR Nasdaq
- DVAX Nasdaq
- Market Cap
- XNCR 1.1B
- DVAX 1.2B
- IPO Year
- XNCR 2013
- DVAX 2004
- Fundamental
- Price
- XNCR $13.86
- DVAX $10.12
- Analyst Decision
- XNCR Buy
- DVAX Buy
- Analyst Count
- XNCR 11
- DVAX 4
- Target Price
- XNCR $24.20
- DVAX $26.50
- AVG Volume (30 Days)
- XNCR 1.5M
- DVAX 1.3M
- Earning Date
- XNCR 11-06-2025
- DVAX 11-05-2025
- Dividend Yield
- XNCR N/A
- DVAX N/A
- EPS Growth
- XNCR N/A
- DVAX N/A
- EPS
- XNCR N/A
- DVAX N/A
- Revenue
- XNCR $146,929,000.00
- DVAX $316,268,000.00
- Revenue This Year
- XNCR $22.09
- DVAX $23.23
- Revenue Next Year
- XNCR N/A
- DVAX $16.57
- P/E Ratio
- XNCR N/A
- DVAX N/A
- Revenue Growth
- XNCR N/A
- DVAX 26.66
- 52 Week Low
- XNCR $6.92
- DVAX $9.20
- 52 Week High
- XNCR $27.24
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- XNCR 55.63
- DVAX 50.46
- Support Level
- XNCR $12.17
- DVAX $10.11
- Resistance Level
- XNCR $15.50
- DVAX $10.58
- Average True Range (ATR)
- XNCR 1.15
- DVAX 0.24
- MACD
- XNCR -0.12
- DVAX 0.02
- Stochastic Oscillator
- XNCR 49.86
- DVAX 53.98
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.